Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support

This article was originally published in The Pink Sheet Daily

Executive Summary

The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.

Advertisement

Related Content

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Keytruda And Opdivo Move Closer To European Marketing Battle
Get Your Priority Review Voucher, While They Last
Retrophin’s New Strategy Gets A Boost, And A Voucher, Thanks To Cholbam
Pediatric Studies: FDA Pushes Earlier Dermatitis Trials; Will It Push Others Next?
Priority Review Vouchers Could Be Used Frequently Next Year
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
United Therapeutics Drops Ovarian Cancer Compound Following Phase III Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel